Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fujioka, Naomi
BTCRC-LUN17-127, NCT03575793: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021 Jun 2021 - Jun 2021: Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021 Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC May 2021 - May 2021: Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021 Apr 2021 - Apr 2021: From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021 More	Completed	1/2	39	US	Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy	Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey	Lung Cancer, SCLC	09/23	07/24
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors	Terminated	1/2	20	US	SQZ-eAPC-HPV, Pembrolizumab	SQZ Biotechnologies	Adult Solid Tumor	11/23	11/23
NCT05674526: A Phase 1b Study of WU-NK-101 in Combination With Cetuximab	Recruiting	1	30	US	WU-NK-101 - Dose Escalation, Cetuximab - Dose Escalation, WU-NK-101 - Cohort Expansion, Cetuximab - Cohort Expansion	Wugen, Inc.	Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck	09/25	06/26